Funding news · Nov 13, 2026

Beyond Medicine Raises Seed Round Led by Yonsei University for Digital TMJ Therapeutic

Beyond Medicine Secures Seed Funding Backed by Yonsei University

Beyond Medicine (비욘드메디슨), a South Korean digital-health company, has raised a Seed round led by Yonsei University (연세대학교). Yonsei University is the sole investor named in the round, investing directly in the company.

The funding amount was not disclosed.

What Beyond Medicine Does

Beyond Medicine is led by CEO Daehyun Kim, a Yonsei-trained dentist. The company builds Clickless, a smartphone-based digital therapeutic for temporomandibular joint (TMJ) disorders.

Clickless pairs a jaw device with a six-week cognitive-behavioral therapy program, delivered through a smartphone. The product received Korean regulatory approval in December 2025.

Why the Round Matters

The investment is notable for its source: Yonsei University has invested directly in the company, tying the startup to the institution where its CEO trained. For a seed-stage digital therapeutic company, direct institutional backing of this kind can support clinical credibility as the company moves toward broader commercialization.

Next Steps: Confirmatory Trials

Beyond Medicine is preparing confirmatory trials as it works toward broader market expansion. Regulatory approval in Korea gives the company a domestic commercial foothold, while the planned confirmatory work points to a path toward wider adoption.

Key Facts

  • Company: Beyond Medicine (비욘드메디슨)
  • Sector: Digital health / digital therapeutics
  • Product: Clickless, a smartphone-based digital therapeutic for TMJ disorders combining a jaw device with a six-week CBT program
  • Regulatory status: Korean approval granted December 2025
  • Round: Seed
  • Lead investor: Yonsei University (연세대학교)
  • Amount: Not disclosed
  • CEO: Daehyun Kim, Yonsei-trained dentist

Acquisition Perspective

Beyond Medicine sits at the intersection of digital therapeutics and dental/ musculoskeletal care, a category where regulatory clearance is a meaningful barrier to entry. Clickless holds Korean approval, and the company is investing in confirmatory trials ahead of broader expansion. For strategic buyers in digital health, medtech, or dental care, the combination of a cleared product, an academic institutional investor, and an ongoing clinical program makes Beyond Medicine a company to watch as it advances toward wider market entry.

© 2026 VeilStrat. All rights reserved.All systems operational